Halozyme (0J2O) Share Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0J2O Analyst Ratings

Moderate Buy

5 Buy

1 Hold

1 Sell

Based on 7 analysts giving stock ratings to

Halozyme

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0J2O Stock 12 Month Forecast

Average Price Target

$97.14

▲(18.39% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $97.14 with a high forecast of $115.00 and a low forecast of $57.00. The average price target represents a 18.39% change from the last price of $82.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","71":"$71","86":"$86","101":"$101","116":"$116"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.14285714285714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$57.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,71,86,101,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.69,85.17538461538462,87.66076923076923,90.14615384615385,92.63153846153845,95.11692307692307,97.60230769230769,100.08769230769231,102.57307692307693,105.05846153846153,107.54384615384615,110.02923076923076,112.51461538461538,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.69,83.80175824175824,84.91351648351647,86.02527472527473,87.13703296703297,88.2487912087912,89.36054945054944,90.4723076923077,91.58406593406593,92.69582417582417,93.80758241758241,94.91934065934066,96.0310989010989,{"y":97.14285714285714,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.69,80.71384615384615,78.7376923076923,76.76153846153846,74.78538461538461,72.80923076923077,70.83307692307692,68.85692307692308,66.88076923076923,64.90461538461538,62.928461538461534,60.95230769230769,58.97615384615385,{"y":57,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.925,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.374,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.585,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.898,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.92,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.52,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.64,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.69,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$115.00

Average Price Target$97.14

Lowest Price Target$57.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

$115

Buy

40.16%

Upside

Reiterated

08/18/26

Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged

David Risinger

Leerink Partners

$83→$110

Buy

34.06%

Upside

Upgraded

08/07/26

Halozyme upgraded to Outperform from Market Perform at LeerinkHalozyme upgraded to Outperform from Market Perform at Leerink

Brendan Smith

TD Cowen

$96→$105

Buy

27.97%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX) and Halozyme (NASDAQ: HALO)

Sean Laaman

Morgan Stanley

$93→$105

Buy

27.97%

Upside

Assigned

08/07/26

Morgan Stanley Remains a Buy on Halozyme (HALO)

Jason Butler

Citizens JMP

$92→$93

Buy

13.35%

Upside

Reiterated

08/07/26

Halozyme price target raised to $93 from $92 at CitizensHalozyme price target raised to $93 from $92 at Citizens

Mohit Bansal

Wells Fargo

$75→$95

Hold

15.78%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)

Corinne Johnson

Goldman Sachs

$57

Sell

-30.53%

Downside

Reiterated

06/14/26

Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)

Unknown Analyst

J.P. Morgan

Not Ranked

J.P. Morgan

$70

Hold

-14.69%

Downside

Reiterated

05/20/26

J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)

Robert Wasserman

Benchmark Co.

$75→$90

Buy

9.69%

Upside

Reiterated

02/19/26

Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

$115

Buy

40.16%

Upside

Reiterated

08/18/26

Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged

David Risinger

Leerink Partners

$83→$110

Buy

34.06%

Upside

Upgraded

08/07/26

Halozyme upgraded to Outperform from Market Perform at LeerinkHalozyme upgraded to Outperform from Market Perform at Leerink

Brendan Smith

TD Cowen

$96→$105

Buy

27.97%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX) and Halozyme (NASDAQ: HALO)

Sean Laaman

Morgan Stanley

$93→$105

Buy

27.97%

Upside

Assigned

08/07/26

Morgan Stanley Remains a Buy on Halozyme (HALO)

Jason Butler

Citizens JMP

$92→$93

Buy

13.35%

Upside

Reiterated

08/07/26

Halozyme price target raised to $93 from $92 at CitizensHalozyme price target raised to $93 from $92 at Citizens

Mohit Bansal

Wells Fargo

$75→$95

Hold

15.78%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)

Corinne Johnson

Goldman Sachs

$57

Sell

-30.53%

Downside

Reiterated

06/14/26

Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)

Unknown Analyst

J.P. Morgan

Not Ranked

J.P. Morgan

$70

Hold

-14.69%

Downside

Reiterated

05/20/26

J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)

Robert Wasserman

Benchmark Co.

$75→$90

Buy

9.69%

Upside

Reiterated

02/19/26

Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

3 Months

Brendan SmithTD Cowen

Success Rate

14/19 ratings generated profit

Average Return

+9.22%

Copying Brendan Smith's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +9.22% per trade.

1 Year

Brendan SmithTD Cowen

Success Rate

19/19 ratings generated profit

Average Return

+36.33%

Copying Brendan Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +36.33% per trade.

2 Years

Brendan SmithTD Cowen

Success Rate

19/19 ratings generated profit

Average Return

+68.97%

Copying Brendan Smith's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +68.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0J2O Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0J2O has received 9 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. 0J2O average Analyst price target in the past 3 months is 97.14.

Each month's total comprises the sum of three months' worth of ratings.

0J2O Financial Forecast

0J2O Earnings Forecast

Next quarter’s earnings estimate for 0J2O is $2.24 with a range of $1.95 to $2.37. The previous quarter’s EPS was $2.28. 0J2O beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0J2O has Performed in-line its overall industry.

0J2O Sales Forecast

Next quarter’s sales forecast for 0J2O is $482.27M with a range of $458.00M to $495.00M. The previous quarter’s sales results were $481.00M. 0J2O beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0J2O has Performed in-line its overall industry.

0J2O Stock Forecast FAQ

What is GB:0J2O’s average 12-month price target, according to analysts?

Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 97.14.

What is GB:0J2O’s upside potential, based on the analysts’ average price target?

Halozyme Therapeutics has 18.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Halozyme Therapeutics a Buy, Sell or Hold?

Halozyme Therapeutics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 1 hold ratings and 1 sell ratings.

What is Halozyme Therapeutics’s share price target?

The average share price target for Halozyme Therapeutics is 97.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $115.00 ,and the lowest forecast is $57.00. The average share price target represents 18.39% Increase from the current price of $82.05.

What do analysts say about Halozyme Therapeutics?

Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Halozyme Therapeutics?

To buy shares of GB:0J2O, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Halozyme (0J2O) Share Forecast & Price Target

0J2O Analyst Ratings

0J2O Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Halozyme

0J2O Analyst Recommendation Trends

0J2O Financial Forecast

0J2O Earnings Forecast

0J2O Sales Forecast

0J2O Stock Forecast FAQ

Detailed List of Analyst Forecasts